DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Biologic Drugs cited in Genzyme Corporation v. Genentech, Inc.
|Date Filed||Document No.||Description||Snippet||Link To Document|
|2016-07-01||77||alterations, deletions or additions[.]’” ECF No. 75-10 at 4 (237). 19 With respect to changes in the amino …antibody.” Cabilly 19 III Patent at 6:66-7:1 (53-54), ECF No. 75-3. The patent contemplates that “[c]hanges…takes issue with the assertion that the Cabilly III patent claims cover 16 Genzyme’s product Lemtrada® in…royalties on that antibody under the Cabilly III patent without suggesting that 19 Genzyme did not require…constant region. See 26 1 The Cabilly III patent issued on April 12, 2011. Lemtrada® was approved||External link to document|
|>Date Filed||>Document No.||>Description||>Snippet||>Link To Document|